Literature DB >> 19249676

MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53.

Martin Enge1, Wenjie Bao, Elisabeth Hedström, Stephen P Jackson, Abdeladim Moumen, Galina Selivanova.   

Abstract

We have previously identified the p53-reactivating compound RITA in a cell-based screen. Here, using microarray analysis, we show that the global transcriptional response of tumor cells to RITA is p53 dependent. Pathway analysis revealed induction of the p53 apoptosis pathway, consistent with apoptosis being the major response to RITA in cancer cells. We uncovered that MDM2 released from p53 by RITA promotes degradation of p21 and the p53 cofactor hnRNP K, required for p21 transcription. Functional studies revealed MDM2-dependent inhibition of p21 as a key switch regulating cell fate decisions upon p53 reactivation. Our results emphasize the utility of targeting wild-type p53 protein itself as a promising approach for anticancer therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19249676     DOI: 10.1016/j.ccr.2009.01.019

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  73 in total

1.  The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias.

Authors:  Kensuke Kojima; Jared K Burks; Janine Arts; Michael Andreeff
Journal:  Mol Cancer Ther       Date:  2010-08-24       Impact factor: 6.261

Review 2.  The regulation of the p53-mediated stress response by MDM2 and MDM4.

Authors:  Mary Ellen Perry
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-01       Impact factor: 10.005

Review 3.  The p53 target Wig-1: a regulator of mRNA stability and stem cell fate?

Authors:  A Vilborg; C Bersani; M T Wilhelm; K G Wiman
Journal:  Cell Death Differ       Date:  2011-03-11       Impact factor: 15.828

4.  SUMOylation of hnRNP-K is required for p53-mediated cell-cycle arrest in response to DNA damage.

Authors:  Seong Won Lee; Moon Hee Lee; Jong Ho Park; Sung Hwan Kang; Hee Min Yoo; Seung Hyun Ka; Young Mi Oh; Young Joo Jeon; Chin Ha Chung
Journal:  EMBO J       Date:  2012-10-23       Impact factor: 11.598

Review 5.  Another fork in the road--life or death decisions by the tumour suppressor p53.

Authors:  Luis A Carvajal; James J Manfredi
Journal:  EMBO Rep       Date:  2013-04-16       Impact factor: 8.807

Review 6.  p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?

Authors:  Aidan P Noon; Nikolina Vlatković; Radosław Polański; Maria Maguire; Howida Shawki; Keith Parsons; Mark T Boyd
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

7.  Increased expression of the heterogeneous nuclear ribonucleoprotein K in pancreatic cancer and its association with the mutant p53.

Authors:  Renyuan Zhou; Reneé Shanas; Mark A Nelson; Achyut Bhattacharyya; Jiaqi Shi
Journal:  Int J Cancer       Date:  2010-01-15       Impact factor: 7.396

8.  Silencing of ribosomal protein S9 elicits a multitude of cellular responses inhibiting the growth of cancer cells subsequent to p53 activation.

Authors:  Mikael S Lindström; Monica Nistér
Journal:  PLoS One       Date:  2010-03-08       Impact factor: 3.240

Review 9.  Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy.

Authors:  Tiffany Devine; Mu-Shui Dai
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 10.  Awakening guardian angels: drugging the p53 pathway.

Authors:  Christopher J Brown; Sonia Lain; Chandra S Verma; Alan R Fersht; David P Lane
Journal:  Nat Rev Cancer       Date:  2009-12       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.